Investment Thesis
Jade Biosciences is a pre-revenue pharmaceutical company with no commercialized products and accelerating operating losses of -$43.4M. With negative free cash flow of -$24.3M annually and only $55.1M in cash, the company faces approximately 2-3 years of runway before requiring additional funding or revenue generation, creating substantial execution risk.
Strengths
- Strong balance sheet with $296.5M stockholders' equity
- Excellent liquidity position with 14.29x current and quick ratios
- Minimal debt burden with 0.00x debt-to-equity ratio and low liabilities at $23.0M
Risks
- Complete absence of revenue indicates no commercialized products or market traction
- Operating losses accelerating with net income deteriorating -27.2% YoY and EPS declining -30.7% YoY
- Negative free cash flow of -$24.3M annually creating limited runway with current cash reserves
- High execution risk typical of pharmaceutical development stage companies dependent on FDA approval and clinical trial success
Key Metrics to Watch
- Revenue generation and commercialization milestones
- Cash burn rate and months of cash runway remaining
- Clinical trial progress and regulatory approval status
Financial Metrics
Revenue
N/A
Net Income
-40.4M
EPS (Diluted)
$-0.57
Free Cash Flow
-24.3M
Total Assets
319.4M
Cash
55.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-13.6%
ROA
-12.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
14.29x
Quick Ratio
14.29x
Debt/Equity
0.00x
Debt/Assets
7.2%
Interest Coverage
-579.27x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T06:44:05.573888 |
Data as of: 2026-03-31 |
Powered by Claude AI